Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma
Abstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein, we evaluated the outc...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5765 |
| _version_ | 1797817611877089280 |
|---|---|
| author | Chen Zhang Jili Deng Yan Xie Lan Mi Weiping Liu Xiaopei Wang Linjun Zhao Yuqin Song Jun Zhu |
| author_facet | Chen Zhang Jili Deng Yan Xie Lan Mi Weiping Liu Xiaopei Wang Linjun Zhao Yuqin Song Jun Zhu |
| author_sort | Chen Zhang |
| collection | DOAJ |
| description | Abstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein, we evaluated the outcomes of single or tandem ASCT in patients with R/R cHL, especially in high‐risk patients. Methods We retrospectively analyzed R/R cHL patients who underwent single or tandem ASCT between April 2000 and June 2021 at the Beijing Cancer Hospital and Peking University International Hospital. Results A total of 134 patients were enrolled. Patients were allocated to a favorable‐risk group (group A, n = 33), an unfavorable‐risk group (group B, n = 81) that underwent single ASCT, and an unfavorable‐risk group that underwent tandem ASCT (group C, n = 20). The median follow‐up time was 99 months (range, 91–107 months), and no treatment‐related deaths occurred after single or tandem ASCT. However, 27 patients (2 in group C) died during the follow‐up period. The groups A, B, and C had 5‐year progression‐free survival (PFS) rates of 77.05%, 45%, and 74.67%, respectively (p = 0.0014), and 5‐year overall survival (OS) rates of 89.85%, 76.06%, and 95%, respectively (p = 0.18). Neither the median PFS rates of groups A and C nor the OS rates of all groups were reached. Conclusions Our study discusses the advantages of tandem transplantation for high‐risk patients with R/R cHL. |
| first_indexed | 2024-03-13T08:56:06Z |
| format | Article |
| id | doaj.art-2324eeada9cd4bddb93f9f17f764330e |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-03-13T08:56:06Z |
| publishDate | 2023-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-2324eeada9cd4bddb93f9f17f764330e2023-05-28T20:33:59ZengWileyCancer Medicine2045-76342023-05-01129103511036210.1002/cam4.5765Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphomaChen Zhang0Jili Deng1Yan Xie2Lan Mi3Weiping Liu4Xiaopei Wang5Linjun Zhao6Yuqin Song7Jun Zhu8Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaDepartment of Lymphoma Peking University International Hospital Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma Peking University Cancer Hospital & Institute Beijing ChinaAbstract Background Autologous stem cell transplantation (ASCT) is the standard treatment strategy for refractory or relapsed classical Hodgkin lymphoma (R/R cHL). However, a single transplantation is insufficient to cure the disease because of unfavorable risk factors. Herein, we evaluated the outcomes of single or tandem ASCT in patients with R/R cHL, especially in high‐risk patients. Methods We retrospectively analyzed R/R cHL patients who underwent single or tandem ASCT between April 2000 and June 2021 at the Beijing Cancer Hospital and Peking University International Hospital. Results A total of 134 patients were enrolled. Patients were allocated to a favorable‐risk group (group A, n = 33), an unfavorable‐risk group (group B, n = 81) that underwent single ASCT, and an unfavorable‐risk group that underwent tandem ASCT (group C, n = 20). The median follow‐up time was 99 months (range, 91–107 months), and no treatment‐related deaths occurred after single or tandem ASCT. However, 27 patients (2 in group C) died during the follow‐up period. The groups A, B, and C had 5‐year progression‐free survival (PFS) rates of 77.05%, 45%, and 74.67%, respectively (p = 0.0014), and 5‐year overall survival (OS) rates of 89.85%, 76.06%, and 95%, respectively (p = 0.18). Neither the median PFS rates of groups A and C nor the OS rates of all groups were reached. Conclusions Our study discusses the advantages of tandem transplantation for high‐risk patients with R/R cHL.https://doi.org/10.1002/cam4.5765refractory or relapsed classical Hodgkin lymphomasingle autologous stem cell transplantationtandem autologous stem cell transplantationunfavorable risk |
| spellingShingle | Chen Zhang Jili Deng Yan Xie Lan Mi Weiping Liu Xiaopei Wang Linjun Zhao Yuqin Song Jun Zhu Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma Cancer Medicine refractory or relapsed classical Hodgkin lymphoma single autologous stem cell transplantation tandem autologous stem cell transplantation unfavorable risk |
| title | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma |
| title_full | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma |
| title_fullStr | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma |
| title_full_unstemmed | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma |
| title_short | Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma |
| title_sort | single or tandem autologous stem cell transplantation for treating chinese patients with refractory relapsed classical hodgkin lymphoma |
| topic | refractory or relapsed classical Hodgkin lymphoma single autologous stem cell transplantation tandem autologous stem cell transplantation unfavorable risk |
| url | https://doi.org/10.1002/cam4.5765 |
| work_keys_str_mv | AT chenzhang singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT jilideng singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT yanxie singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT lanmi singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT weipingliu singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT xiaopeiwang singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT linjunzhao singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT yuqinsong singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma AT junzhu singleortandemautologousstemcelltransplantationfortreatingchinesepatientswithrefractoryrelapsedclassicalhodgkinlymphoma |